Jobs
-
Inhaled nitric oxide developer Third Pole Therapeutics has announced the appointment of Bill Athenson as its new Chief Executive Officer, succeeding founding CEO David Zapol. Athenson most recently served as CEO of Three Lakes Partners;… Read more . . .
-
Inhaled drug developer Vectura has announced the appointment of former Catalent executive Will Downie as CEO and Executive Director. Downie was most recently Senior VP, Global Sales and Marketing at Catalent and previously served in… Read more . . .
-
CDMO Micro-Sphere has announced an investment of 3.5 million CHF (~$3.5 million) that will include the addition of a fifth spray drying line to its GMP facility in Switzerland. The new line should be in… Read more . . .
-
Dry powder inhaler developer Iconovo has announced that the company will invest approximately 20 million SEK over about 3 years to develop a new platform for development of generic versions of Ellipta DPI products. The… Read more . . .
-
Bryn Pharma, which recently announced that it would use Aptar’s Bidose nasal device for delivery of its BRYN-NDS1C intranasal epinephrine, said that it has raised $17.5 million that it will use to prepare for US… Read more . . .
-
TFF Pharmaceuticals, which is developing DPI formulations based on its thin film freezing (TFF) technology, has announced an initial public offering of 4,400,000 shares of common stock at $5.00 per share. Earlier this year TFF… Read more . . .
-
Medical Developments International (MDI) has announced data from multiple European studies demonstrating the benefits of MDI’s Penthrox methoxyflurane inhaler for the treatment of pain from acute trauma. Among the findings announced, Penthrox was shown to… Read more . . .
-
The FDA has cleared BlueWillow Biologics’ IND for its BW-1010 intranasal anthrax vaccine, and a Phase 1 trial of the vaccine is planned for later this year, the company said. Earlier this year, BlueWillow (formerly… Read more . . .
-
Seelos Therapeutics has announced an amendment of its agreement with Vyera Pharmaceuticals regarding development of SLS-002 intranasal ketamine. According to Seelos, the company will now not be required to conduct a Phase 3 trial and… Read more . . .
-
HCmed Innovations has introduced its new Pulmogine mesh nebulizer, which is capable of delivering a variety of drugs for inhalation, including biologics and high viscosity solutions. The nebulizer is customizable for specific formulations, and the… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany